Objective: This review examines the evidence of neural inhibition as a mechanism underlying pain relief and anesthetic effect of photobiomodulation (PBM). Background: PBM for pain relief has also been used for more than 30 years; however, the mechanism of its effectiveness has not been well understood. Methods: We review electrophysiological studies in humans and animal models and cell culture studies to examine neural responses to PBM. Results: Evidence shows that PBM can inhibit nerve function in vivo , in situ , ex vivo , and in culture. Animal studies using noxious stimuli indicate nociceptor-specific inhibition with other studies providing direct evidence of local conduction block, leading to inhibited translation of pain centrally. Evidence of PBM-disrupted neuronal physiology affecting axonal flow, cytoskeleton organization, and decreased ATP is also presented. PBM changes are reversible with no side effects or nerve damage. Conclusions: This review provides strong evidence in neuroscience identifying inhibition of neural function as a mechanism for the clinical application of PBM in pain and anesthesia
1 September 2012 in Photomedicine and Laser Surgery
Objective: The purpose of this study was to evaluate effects of transcutaneous 650 and 808 nm laser irradiation (LI) to a single point overlying rat sciatic nerve; a comparison to four point LI and relevance to the clinical application of low-level laser therapy (LLLT) and laser acupuncture (LA). Background data: Transcutaneous LI inhibits somatosensory and motor conduction when delivered to four points overlying sciatic nerve; however, effects of the same total energy delivered to a single point over the nerve, equating to laser acupuncture, are undefined. Methods: Transcutaneous 808 nm, 450 mW, (13.5 or 54 J) continuous wave (cw) mode or 650 nm, 35 mW, (1.1 or 4.4 J), cw LI or sham LI, was applied for 30 or 120 sec to a single point overlying the midpoint of rat sciatic nerve. Somatosensory evoked potentials (SSEPs) and compound muscle action potentials (CMAPs) were then recorded after 10 and 20 min, and after 24 and 48 h. Results: 120 sec of 808 nm LI increased SSEP amplitudes only at 10 min, with no effect of 30 or 120 sec at other time points on SSEPs or on CMAPs. LI 650 nm for 30 or 120 sec did not alter SSEPs or CMAPs at any time point. Conclusions: Localized transcutaneous 808 LI to a single point overlying sciatic nerve increases SSEP amplitudes when compared with delivery of the same total energy to four points, which causes decreased SSEP amplitudes and conduction block. Therefore, the area and duration of delivery are important, independent variables with implications for clinical delivery of both LLLT and LA.
This narrative review analyses the Australian Guideline (2018) for the treatment of knee osteoarthritis (KOA) developed using Grading of Recommendations Assessment, Development, and Evaluation (GRADE) methodology. The Guideline recommended against the use low-level laser therapy (LLLT). Why this conclusion was reached is discussed in this review in the context of evidence provided in other systematic reviews, the latest of which was published in 2019 and which provided strong support for LLLT for knee OA. We evaluated the reference list cited for the recommendation “against” LLLT and compared this with reference lists of systematic reviews and studies published before and after the publication date of the Guideline. Eight randomised controlled trials (RCTs) of LLLT were cited in the Guideline the latest of which was published in 2012. There were seventeen additional RCTs, five of which together with one systematic review were located in the year of publication, 2018. The most recent systematic review in 2019 included 22 RCTs in its analysis. Discordance with the levels of evidence and recommendations was identified. Although GRADE methodology is said to be robust for systematically evaluating evidence and developing recommendations, many studies were not identified in the Guideline. In contrast, the latest systematic review and meta-analysis provides robust evidence for supporting the use of LLLT in knee OA. The conflict between guidelines based on opinion and evidence based on meta-analysis is highlighted. Given the totality of the evidence, we recommend that the Australian Guideline should be updated immediately to reflect a “for” recommendation.
Background/Objectives: Photobiomodulation (PBM) therapy has shown potential in managing orofacial neuropathic pain (ONP); however, inconsistent PBM dosimetry and methodological variability limit its clinical application. This World Association for Photobiomodulation Therapy (WALT) Position Paper aims to critically appraise current evidence and provide recommendations for Clinical Practice Guidelines (CPG) and Expert Consensus Opinion (ECO) where appropriate. Methods: Evidence evaluation was guided by the HANNA (Holistic Analysis & Novel Normative Actions) Framework, a structured multi-step methodology integrating systematic review, quality appraisal, and expert consensus. A systematic review was conducted in accordance with PRISMA 2020 guidelines. Methodological quality was assessed using validated tools: AMSTAR 2 for systematic reviews, RoB2 for randomized controlled trials (RCTs), and ROBINS-I for non-randomized studies (NRCTs). The AGREE II Reporting Checklist was applied to ensure transparency and rigor in the development of WALT recommendations. The Somerfield Criteria were used to rate the level of evidence (LoE) for each included ONP condition, where deemed appropriate. Results: WALT CPG were established for primary burning mouth syndrome (BMS), supported by robust evidence (LoE I) from 204 patients across six “Low RoB” RCTs and NRCTs, and 557 patients included in a “High-Confidence” systematic review and meta-analysis of “low RoB” RCTs. WALT ECO were developed for idiopathic trigeminal neuralgia (TN) and post-herpetic neuralgia (PHN), both supported by LoE II. Insufficient evidence precluded formal recommendations for post-traumatic trigeminal neuralgia, glossopharyngeal neuralgia, and occipital neuralgia. Conclusions: This Position Paper introduces the HANNA Framework, for the first time, as a robust and transparent methodology for developing WALT recommendations by delivering evidence-based CPG for PBM in the management of neuropathic pain associated with primary BMS, along with ECO for both TN and PHN. These recommendations support PBM as a safe and effective therapeutic approach, and provide a structured roadmap for future research and periodic guidelines updates.
The use of light (photons) delivered clinically from laser or light-emitting diodes (LED), is referred to as photobiomodulation therapy (PBMt). Increasingly PBMt is accepted particularly in dental practice for pain or pre-emptive anaesthesia. Understanding its mechanism of effectiveness is the key to its increasing acceptance. Of major importance to this is how PBMt affects not only the neurons but also the Schwann cells and fibroblasts of the peripheral nervous system which are unique in morphology and function. The specific roles of the neuronal cells of the dorsal root and trigeminal ganglia, now include consideration of the axon initial segment responsible for the initiation of the action potential and the T junction from which the distal and proximal axons arise which are complex but central to normal function. This cellular complexity, organization and function is discussed leading to a review of the mechanism of effectiveness of PBMt demonstrated by clinical trials in both medicine and dentistry. This review provides evidence of the involvement of the cytoskeleton, mitochondrial organization particularly related to fast and slow axonal flow and mitochondrial membrane potential in response to light in somatosensory neurons and nerves.
This review aims to provide a translational link between clinical evidence in the application of photobiomodulation for treatment of painful conditions in medicine and dentistry and neurophysiological effects of photobiomodulation therapy (PBMt). PBMt is gaining increasing acceptance as a therapeutic modality for pain management, particularly within dental practice. However, a clearer understanding of its mechanisms of action remains essential for broader clinical adoption and integration into mainstream healthcare. Central to the therapeutic effects of PBMt for pain is its interaction with neurons, which possess unique structural and functional characteristics. Advances in our understanding of the cellular architecture of dorsal root and trigeminal ganglion neurons highlight the importance of the stem axon and axon initial segment (AIS), a specialized region adjacent to the axon hillock that is now recognized as the principal site of action potential initiation. These developments have important implications for understanding the biological effects of PBMt and its clinical application. This review synthesizes evidence demonstrating that PBM influences cytoskeletal organization, mitochondrial structure and function, and intracellular signaling pathways, with downstream effects on neuronal excitability and nerve conduction. By integrating findings from cellular, neurophysiological, and clinical studies, the review examines how these mechanistic effects may contribute to pain modulation and analgesia.